EOLS - Evolus GAAP EPS of -$0.26 misses by $0.01 revenue of $41.7M beats by $1.18M
2023-05-09 16:08:18 ET
- Evolus press release ( NASDAQ: EOLS ): Q1 GAAP EPS of -$0.26 misses by $0.01 .
- Revenue of $41.7M (+23.0% Y/Y) beats by $1.18M .
- Evolus continues to expect total net revenues for the full year 2023 to be between $180 million and $190 million, representing year-over-year growth of 21% to 28% and more than double the estimated growth rate of the aesthetic neurotoxin market.
- The company expects its adjusted gross profit margin for the full year 2023 to be between 68% and 71%.
- Evolus now expects its full-year non-GAAP operating expenses to be between $153 million and $158 million.
- The company now projects its total net revenue 3 can reach $700 million by 2028,
For further details see:
Evolus GAAP EPS of -$0.26 misses by $0.01, revenue of $41.7M beats by $1.18M